France
In April 2022, the company secured a significant €1.50M Debt Financing investment, with the support of Bpifrance. This injection of capital not only showcases the confidence that investors have in the company's mission but also provides Priothera with the resources necessary to further develop and advance its groundbreaking approach.
As a startup operating in the fields of biotechnology, healthcare, and pharmaceuticals, Priothera is positioned within highly impactful industries. With its innovative solution addressing a pressing medical need, the company has the potential to make a significant difference in the lives of patients. The recent investment represents a crucial stepping stone in Priothera's journey to revolutionize treatment options for hematological malignancies.
